Gainers

• Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million.
• LENSAR (NASDAQ:LNSR) shares increased by 20.19% to $7.56. The company's market cap stands at $77.2 million. The company's, Q2 earnings came out today.
• NRC Health (NASDAQ:NRC) stock increased by 16.44% to $24.0. The market value of their outstanding shares is at $455.8 million.
• Omeros (NASDAQ:OMER) shares moved upwards by 15.99% to $15.9. The company's market cap stands at $992.2 million. As per the news, the Q2 earnings report came out yesterday.
• Cullinan Therapeutics (NASDAQ:CGEM) stock rose 12.27% to $22.0. The market value of their outstanding shares is at $1.2 billion.
• Journey Medical (NASDAQ:DERM) stock rose 11.04% to $7.14. The company's market cap stands at $177.0 million. The company's, Q2 earnings came out yesterday.

Losers

• Outlook Therapeutics (NASDAQ:OTLK) stock decreased by 25.7% to $0.82 during Thursday's pre-market session. The company's market cap stands at $205.6 million.
• Valion Bio (NASDAQ:VBIO) shares declined by 25.67% to $0.17.
• Curis (NASDAQ:CRIS) stock declined by 19.17% to $1.35. The market value of their outstanding shares is at $3.4 million.
• Abeona Therapeutics (NASDAQ:ABEO) stock declined by 17.97% to $6.12. The market value of their outstanding shares is at $425.1 million. As per the news, the Q2 earnings report came out today.
• Contineum Therapeutics (NASDAQ:CTNM) stock declined by 17.49% to $12.36. The company's market cap stands at $563.5 million.
• Dermata Therapeutics (NASDAQ:DRMA) shares declined by 15.22% to $1.17. The company's market cap stands at $5.5 million. As per the press release, Q2 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.